Wow again highlights how cheap NEU is on the ASX. Either we are...

Wow

again highlights how cheap NEU is on the ASX. Either we are getting t/o at a large premium to put us in line with overseas activity or we are getting a deal that has ridiculously large (multi bill) back ended development milestones. Given Retts is a potential $1.5 bill market in the USA and Fragile X is $7-8 bill (based on the average orphan drug price) then we must be in for a whopping deal. That excludes sales in the rest of the world. Normally the USA market accounts for 60% of global sales.. roughly.